Display options
Cite
Gomaa AI, Al-Khatib A, Abdel-Razek W, et al. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol. 2015;21(18):5654-62doi: 10.3748/wjg.v21.i18.5654.
Gomaa, A. I., Al-Khatib, A., Abdel-Razek, W., Hashim, M. S., & Waked, I. (2015). Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World journal of gastroenterology, 21(18), 5654-62. https://doi.org/10.3748/wjg.v21.i18.5654
Gomaa, Asmaa I, et al. "Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging." World journal of gastroenterology vol. 21,18 (2015): 5654-62. doi: https://doi.org/10.3748/wjg.v21.i18.5654
Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World J Gastroenterol. 2015 May 14;21(18):5654-62. doi: 10.3748/wjg.v21.i18.5654. PMID: 25987792; PMCID: PMC4427691.
Copy Download .nbib Format: NLM
Share it on

World J Gastroenterol. 2015 May 14;21(18):5654-62. doi: 10.3748/wjg.v21.i18.5654.

Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.

World journal of gastroenterology

Asmaa I Gomaa, Alzhraa Al-Khatib, Wael Abdel-Razek, Mohammed Saad Hashim, Imam Waked

Affiliations

  1. Asmaa I Gomaa, Wael Abdel-Razek, Mohammed Saad Hashim, Imam Waked, Hepatology Department, National Liver Institute, Menoufiya University, Shebeen El-Kom 35111, Egypt.

PMID: 25987792 PMCID: PMC4427691 DOI: 10.3748/wjg.v21.i18.5654

Abstract

AIM: To assess how ascites and alpha-fetoprotein (AFP) added to the Barcelona Clinic Liver Cancer (BCLC) staging predict hepatocellular carcinoma survival.

METHODS: The presence of underlying cirrhosis, ascites and encephalopathy, Child-Turcotte-Pugh (CTP) score, the number of nodules, and the maximum diameter of the largest nodule were determined at diagnosis for 1060 patients with hepatocellular carcinoma at a tertiary referral center for liver disease in Egypt. Demographic information, etiology of liver disease, and biochemical data (including serum bilirubin, albumin, international normalized ratio, alanine and aspartate aminotransferases, and AFP) were evaluated. Staging of the tumor was determined at the time of diagnosis using the BCLC staging system; 496 patients were stage A and 564 patients were stage B. Patients with mild ascites on initial ultrasound, computed tomography, or clinical examination, and who had a CTP score ≤ 9 were included in this analysis. All patients received therapy according to the recommended treatment based on the BCLC stage, and were monitored from the time of diagnosis to the date of death or date of data collection. The effect of the presence of ascites and AFP level on survival was analyzed.

RESULTS: At the time the data were censored, 123/496 (24.8%) and 218/564 (38.6%) patients with BCLC stages A and B, respectively, had died. Overall mean survival of the BCLC A and B patients during a three-year follow-up period was 31 mo [95% confidence interval (95%CI): 29.7-32.3] and 22.7 mo (95%CI: 20.7-24.8), respectively. The presence of ascites, multiple focal lesions, large tumor size, AFP level and CTP score were independent predictors of survival for the included patients on multivariate analysis (P < 0.001). Among stage A patients, 18% had ascites, 33% had AFP ≥ 200 ng/mL, and 8% had both. Their median survival in the presence of ascites was shorter if AFP was ≥ 200 ng/mL (19 mo vs 24 mo), and in the absence of ascites, patients with AFP ≥ 200 ng/mL had a shorter survival (28 mo vs 39 mo). For stage B patients, survival for the corresponding groups was 12, 18, 19 and 22 mo. The one-, two-, and three-year survival rates for stage A patients without ascites and AFP < 200 ng/mL were 94%, 77%, and 71%, respectively, and for patients with ascites and AFP ≥ 200 ng/mL were 83%, 24%, and 22%, respectively (P < 0.001). Adding ascites and AFP ≥ 200 ng/mL improved the discriminatory ability for predicting prognosis (area under the curve, 0.618 vs 0.579 for BCLC, P < 0.001).

CONCLUSION: Adding AFP and ascites to the BCLC staging classification can improve prognosis prediction for early and intermediate stages of hepatocellular carcinoma.

Keywords: Alpha-fetoprotein; Ascites; Barcelona Clinic Liver Cancer; Hepatocellular carcinoma; Survival

References

  1. Hepatology. 2011 Mar;53(3):1020-2 - PubMed
  2. Semin Liver Dis. 1999;19(3):329-38 - PubMed
  3. Int J Cancer. 2004 Oct 20;112(1):44-50 - PubMed
  4. Aliment Pharmacol Ther. 2008 Jul;28(1):62-75 - PubMed
  5. Liver Transpl. 2004 Sep;10(9):1195-202 - PubMed
  6. J Hepatol. 2004 Jan;40(1):124-31 - PubMed
  7. Semin Liver Dis. 2012 Nov;32(4):348-59 - PubMed
  8. J Gastroenterol Hepatol. 2008 Mar;23(3):445-52 - PubMed
  9. Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):256-61 - PubMed
  10. Ann Oncol. 2008 Jun;19(6):1117-26 - PubMed
  11. Int J Cancer. 2007 Jun 15;120(12):2650-5 - PubMed
  12. Gut. 2005 Mar;54(3):411-8 - PubMed
  13. Eur J Surg Oncol. 2007 May;33(4):480-7 - PubMed
  14. J Hepatol. 2008;48 Suppl 1:S20-37 - PubMed
  15. Clin Radiol. 2012 May;67(5):429-36 - PubMed
  16. Radiology. 1982 Apr;143(1):29-36 - PubMed
  17. World J Gastroenterol. 2005 Aug 7;11(29):4465-71 - PubMed
  18. Eur J Surg Oncol. 2013 Aug;39(8):850-7 - PubMed
  19. Hepatology. 2012 Aug;56(2):614-21 - PubMed
  20. J Gastrointestin Liver Dis. 2013 Sep;22(3):291-7 - PubMed
  21. Am J Gastroenterol. 2008 Mar;103(3):597-604 - PubMed
  22. Lancet. 2003 Dec 6;362(9399):1907-17 - PubMed
  23. Transplantation. 2013 Jan 15;95(1):228-33 - PubMed
  24. Cancer. 2008 Jan 15;112(2):352-61 - PubMed
  25. Hepatology. 2010 Apr;51(4):1274-83 - PubMed
  26. Oncology. 2011;81(3-4):251-8 - PubMed
  27. PLoS One. 2012;7(10):e45066 - PubMed
  28. PLoS One. 2011;6(9):e23093 - PubMed
  29. Am J Gastroenterol. 2006 May;101(5):975-82 - PubMed
  30. Oncologist. 2010;15 Suppl 4:23-33 - PubMed
  31. J Hepatol. 2006 Apr;44(4):723-31 - PubMed
  32. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  33. Hepatol Res. 2002 Dec;24(4):395-403 - PubMed
  34. J Hepatol. 2012 Apr;56(4):908-43 - PubMed
  35. PLoS One. 2014;9(3):e90929 - PubMed

Substances

MeSH terms

Publication Types